Markets

Health Care Sector Update for 01/21/2015: TROV, UNH, CRIS

Top Health-care stocks:

JNJ: -0.2%

PFE: flat

ABT: flat

MRK: flat

AMGN: flat

Health-care shares were generally unchanged in pre-market trade Wednesday.

In health-care stocks news, Trovagene ( TROV ) Wednesday reported it will expand clinical studies with the Genomac Research Institute in Prague, Czech Republic into the early detection of emerging oncogene mutations indicative of resistance to targeted therapies used to treat colorectal and lung cancer.

Shares in the company were unchanged at $6.00 during Wednesday's pre-market trading session. Over the past 52 weeks, the company has traded between $2.97 and $7.10.

Meanwhile UnitedHealth Group ( UNH ) a health care coverage provider, reported Q4 results that beat the Street view on both EPS and total revenues, fueled by growth in its Optum segment. The company reported Q4 EPS of $1.55, up from $1.41 in the same period a year ago and beating analyst estimates of $1.50.

Shares in the company were up 0.8% during pre-market trading at $106.50, a new 52-week high. Over the previous 52 weeks, the company had traded between $69.57 and $106.38.

And Curis ( CRIS ) Wednesday reported it will collaborate with Aurigene Discovery Technologies to study cancer therapies, and that CRIS will have an option to exclusively license cancer-fighting compounds developed.

In connection with the transaction, CRIS reported it issued to Aurigene 17.1 million common shares, or 19.9% of shares outstanding, subject to a lock-up agreement until Jan. 18, 2017.

Shares in the company were unchanged at $1.40 during Wednesday's pre-market trading session. Over the past 52 weeks, the company has traded between $1.09 and $3.40.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

TROV UNH CRIS

Other Topics

Commodities